LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 490

Search options

  1. Article ; Online: Checkpoint blockade: the end of the beginning.

    Wolchok, Jedd D

    Nature reviews. Immunology

    2021  Volume 21, Issue 10, Page(s) 621

    Language English
    Publishing date 2021-09-27
    Publishing country England
    Document type Journal Article
    ZDB-ID 2062776-2
    ISSN 1474-1741 ; 1474-1733
    ISSN (online) 1474-1741
    ISSN 1474-1733
    DOI 10.1038/s41577-021-00617-9
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Having the cake and eating it? Clofazimine boosts immunotherapy while limiting side effects.

    Kraehenbuehl, Lukas / Wolchok, Jedd D / Merghoub, Taha / Hirschhorn, Daniel

    Cancer cell

    2024  

    Abstract: Combined immune checkpoint blockade (ICB) for cancer exhibits good efficacy in a subset of patients but also associates with immune-related adverse events. Xue et al. use an elegant drug screening strategy to identify the antimicrobial drug clofazimine ... ...

    Abstract Combined immune checkpoint blockade (ICB) for cancer exhibits good efficacy in a subset of patients but also associates with immune-related adverse events. Xue et al. use an elegant drug screening strategy to identify the antimicrobial drug clofazimine as an agent that both potentiates ICB efficacy and decreases immune-related adverse events.
    Language English
    Publishing date 2024-03-25
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2078448-X
    ISSN 1878-3686 ; 1535-6108
    ISSN (online) 1878-3686
    ISSN 1535-6108
    DOI 10.1016/j.ccell.2024.03.007
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Altered self: the not-so-neo-antigens.

    Wolchok, Jedd D

    Nature reviews. Immunology

    2018  Volume 18, Issue 3, Page(s) 152

    MeSH term(s) Antigens ; Antigens, Differentiation ; Autoimmunity ; Biomarkers ; Humans ; Neoplasms
    Chemical Substances Antigens ; Antigens, Differentiation ; Biomarkers
    Language English
    Publishing date 2018-02-05
    Publishing country England
    Document type Journal Article ; Comment
    ZDB-ID 2062776-2
    ISSN 1474-1741 ; 1474-1733
    ISSN (online) 1474-1741
    ISSN 1474-1733
    DOI 10.1038/nri.2018.7
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Reply to: Combining TNF blockade with immune checkpoint inhibitors in patients with cancer.

    Chen, Allen Y / Wolchok, Jedd D / Bass, Anne R

    Nature reviews. Rheumatology

    2021  Volume 17, Issue 9, Page(s) 577–578

    MeSH term(s) Humans ; Immune Checkpoint Inhibitors ; Immunotherapy ; Neoplasms/drug therapy
    Chemical Substances Immune Checkpoint Inhibitors
    Language English
    Publishing date 2021-07-05
    Publishing country United States
    Document type Letter ; Comment
    ZDB-ID 2491532-4
    ISSN 1759-4804 ; 1759-4790
    ISSN (online) 1759-4804
    ISSN 1759-4790
    DOI 10.1038/s41584-021-00654-7
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: PD-L1 Blockade Therapy: Location, Location, Location.

    Brown, Chrysothemis C / Wolchok, Jedd D

    Cancer cell

    2020  Volume 38, Issue 5, Page(s) 615–617

    Abstract: The mechanisms by which PD-1/PD-L1 inhibition elicits anti-tumor immunity are not fully understood. In this issue of Cancer Cell, Dammeijer et al. address the role of PD-L1 inhibition specifically within the tumor-draining lymph node, identifying a ... ...

    Abstract The mechanisms by which PD-1/PD-L1 inhibition elicits anti-tumor immunity are not fully understood. In this issue of Cancer Cell, Dammeijer et al. address the role of PD-L1 inhibition specifically within the tumor-draining lymph node, identifying a potential role for PD-L1 expressing dendritic cells within the lymph node in regulation of anti-tumor immune responses.
    MeSH term(s) B7-H1 Antigen ; Cell Line, Tumor ; Lymph Nodes ; Programmed Cell Death 1 Receptor ; T-Lymphocytes
    Chemical Substances B7-H1 Antigen ; Programmed Cell Death 1 Receptor
    Language English
    Publishing date 2020-11-29
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't ; Comment
    ZDB-ID 2078448-X
    ISSN 1878-3686 ; 1535-6108
    ISSN (online) 1878-3686
    ISSN 1535-6108
    DOI 10.1016/j.ccell.2020.10.017
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Reply to T. Olivier et al.

    Wolchok, Jedd D / Kluger, Harriet / Campigotto, Federico / Larkin, James / Hodi, F Stephen

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology

    2022  Volume 40, Issue 14, Page(s) 1597–1598

    Language English
    Publishing date 2022-03-08
    Publishing country United States
    Document type Research Support, Non-U.S. Gov't ; Research Support, N.I.H., Extramural ; Letter ; Comment
    ZDB-ID 604914-x
    ISSN 1527-7755 ; 0732-183X
    ISSN (online) 1527-7755
    ISSN 0732-183X
    DOI 10.1200/JCO.22.00209
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: The many faces of the anti-COVID immune response.

    Vardhana, Santosha A / Wolchok, Jedd D

    The Journal of experimental medicine

    2020  Volume 217, Issue 6

    Abstract: The novel 2019 strain of coronavirus is a source of profound morbidity and mortality worldwide. Compared with recent viral outbreaks, COVID-19 infection has a relatively high mortality rate, the reasons for which are not entirely clear. Furthermore, ... ...

    Abstract The novel 2019 strain of coronavirus is a source of profound morbidity and mortality worldwide. Compared with recent viral outbreaks, COVID-19 infection has a relatively high mortality rate, the reasons for which are not entirely clear. Furthermore, treatment options for COVID-19 infection are currently limited. In this Perspective, we explore the contributions of the innate and adaptive immune systems to both viral control as well as toxicity during COVID-19 infections and offer suggestions to both understand and therapeutically modulate anti-COVID immunity.
    MeSH term(s) Adaptive Immunity/drug effects ; Adaptive Immunity/immunology ; Betacoronavirus/drug effects ; Betacoronavirus/immunology ; Betacoronavirus/pathogenicity ; COVID-19 ; Coronavirus Infections/immunology ; Coronavirus Infections/pathology ; Coronavirus Infections/therapy ; Cytokine Release Syndrome/immunology ; Cytokine Release Syndrome/pathology ; Cytokine Release Syndrome/therapy ; Humans ; Hypoxia/pathology ; Hypoxia/therapy ; Immunity, Innate/drug effects ; Immunity, Innate/immunology ; Inflammation/immunology ; Inflammation/pathology ; Inflammation/therapy ; Interleukin-6/antagonists & inhibitors ; Interleukin-6/immunology ; Lymphopenia/immunology ; Lymphopenia/pathology ; Lymphopenia/therapy ; Macrophages/immunology ; Macrophages/pathology ; Middle East Respiratory Syndrome Coronavirus/immunology ; Middle East Respiratory Syndrome Coronavirus/pathogenicity ; Pandemics ; Pneumonia, Viral/immunology ; Pneumonia, Viral/pathology ; Pneumonia, Viral/therapy ; Respiration, Artificial ; Respiratory Distress Syndrome/pathology ; Respiratory Distress Syndrome/therapy ; Severe acute respiratory syndrome-related coronavirus/immunology ; Severe acute respiratory syndrome-related coronavirus/pathogenicity ; SARS-CoV-2
    Chemical Substances Interleukin-6
    Keywords covid19
    Language English
    Publishing date 2020-04-28
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 218343-2
    ISSN 1540-9538 ; 0022-1007
    ISSN (online) 1540-9538
    ISSN 0022-1007
    DOI 10.1084/jem.20200678
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Eradicating micrometastases with immune checkpoint blockade: Strike while the iron is hot.

    Janjigian, Yelena Y / Wolchok, Jedd D / Ariyan, Charlotte E

    Cancer cell

    2021  Volume 39, Issue 6, Page(s) 738–742

    Abstract: Immune checkpoint blockade (ICB) is transforming treatment for many cancers. While ICB alone initially demonstrated efficacy in patients with metastatic melanoma, it has expanded to other types and to earlier-stage cancers. We describe ICB history, ... ...

    Abstract Immune checkpoint blockade (ICB) is transforming treatment for many cancers. While ICB alone initially demonstrated efficacy in patients with metastatic melanoma, it has expanded to other types and to earlier-stage cancers. We describe ICB history, mechanisms underlying variation in response, and how ICB is being integrated into adjuvant and neoadjuvant treatment approaches.
    MeSH term(s) Circulating Tumor DNA/blood ; Clinical Trials as Topic ; Humans ; Immune Checkpoint Inhibitors/pharmacology ; Neoplasm Micrometastasis/drug therapy ; Neoplasm Micrometastasis/pathology ; Organ Sparing Treatments
    Chemical Substances Circulating Tumor DNA ; Immune Checkpoint Inhibitors
    Language English
    Publishing date 2021-06-12
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 2078448-X
    ISSN 1878-3686 ; 1535-6108
    ISSN (online) 1878-3686
    ISSN 1535-6108
    DOI 10.1016/j.ccell.2021.05.013
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Recruit or Reboot? How Does Anti-PD-1 Therapy Change Tumor-Infiltrating Lymphocytes?

    Callahan, Margaret K / Wolchok, Jedd D

    Cancer cell

    2019  Volume 36, Issue 3, Page(s) 215–217

    Abstract: It has been widely assumed that PD-1 blockade works by reinvigorating ("rebooting") pre-existing exhausted tumor-infiltrating ilymphocytes (TILs). A recent study challenges this paradigm, demonstrating that the majority of tumor-specific TILs after anti- ... ...

    Abstract It has been widely assumed that PD-1 blockade works by reinvigorating ("rebooting") pre-existing exhausted tumor-infiltrating ilymphocytes (TILs). A recent study challenges this paradigm, demonstrating that the majority of tumor-specific TILs after anti-PD-1 treatment have TCRs not identified in the tumor pre-therapy, suggesting they are newly recruited post-therapy.
    MeSH term(s) CD8-Positive T-Lymphocytes ; Humans ; Lymphocytes, Tumor-Infiltrating ; Neoplasms ; Programmed Cell Death 1 Receptor
    Chemical Substances Programmed Cell Death 1 Receptor
    Language English
    Publishing date 2019-09-13
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't ; Comment
    ZDB-ID 2078448-X
    ISSN 1878-3686 ; 1535-6108
    ISSN (online) 1878-3686
    ISSN 1535-6108
    DOI 10.1016/j.ccell.2019.08.009
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Clinical implications of T cell exhaustion for cancer immunotherapy.

    Chow, Andrew / Perica, Karlo / Klebanoff, Christopher A / Wolchok, Jedd D

    Nature reviews. Clinical oncology

    2022  Volume 19, Issue 12, Page(s) 775–790

    Abstract: Immunotherapy has been a remarkable clinical advancement in the treatment of cancer. T cells are pivotal to the efficacy of current cancer immunotherapies, including immune-checkpoint inhibitors and adoptive cell therapies. However, cancer is associated ... ...

    Abstract Immunotherapy has been a remarkable clinical advancement in the treatment of cancer. T cells are pivotal to the efficacy of current cancer immunotherapies, including immune-checkpoint inhibitors and adoptive cell therapies. However, cancer is associated with T cell exhaustion, a hypofunctional state characterized by progressive loss of T cell effector functions and self-renewal capacity. The 'un-exhausting' of T cells in the tumour microenvironment is commonly regarded as a key mechanism of action for immune-checkpoint inhibitors, and T cell exhaustion is considered a pathway of resistance for cellular immunotherapies. Several elegant studies have provided important insights into the transcriptional and epigenetic programmes that govern T cell exhaustion. In this Review, we highlight recent discoveries related to the immunobiology of T cell exhaustion that offer a more nuanced perspective beyond this hypofunctional state being entirely undesirable. We review evidence that T cell exhaustion might be as much a reflection as it is the cause of poor tumour control. Furthermore, we hypothesize that, in certain contexts of chronic antigen stimulation, interruption of the exhaustion programme might impair T cell persistence. Therefore, the prioritization of interventions that mitigate the development of T cell exhaustion, including orthogonal cytoreduction therapies and novel cellular engineering strategies, might ultimately confer superior clinical outcomes and the greatest advances in cancer immunotherapy.
    MeSH term(s) Humans ; T-Lymphocytes ; Immune Checkpoint Inhibitors ; Immunotherapy ; Immunotherapy, Adoptive ; Tumor Microenvironment ; Neoplasms
    Chemical Substances Immune Checkpoint Inhibitors
    Language English
    Publishing date 2022-10-10
    Publishing country England
    Document type Journal Article ; Review ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 2491410-1
    ISSN 1759-4782 ; 1759-4774
    ISSN (online) 1759-4782
    ISSN 1759-4774
    DOI 10.1038/s41571-022-00689-z
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top